P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN(®)-multiantigen vaccine: high responder rate and considerable breadth of immunological response

por Overton, T, Schmidt, D, Hain, J, Virgin, G, Steigerwald, R, Dirmeier, U, Jordan, E, Meyer, T, Young, P, Ludvigsen, A, Nichols, R, Chaplin, P
Publicado 2009